Concepedia

Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

Maxime Le Merdy, Ming‐Liang Tan, Dajun Sun, Zhanglin Ni, Sue‐Chih Lee, Andrew Babiskin, Liang Zhao

European Journal of Drug Metabolism and Pharmacokinetics · 2020 · 10 citations · 20 references

DOI

Concepts

References

20

Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

F. Peter Guengerich, M V Martin, Philippe Beaune et al. · Journal of Biological Chemistry · 1986 · 730 citations · Full text

, , +17

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xueqing Li, Tommy B. Andersson, Marie M. Ahlström et al. · Drug Metabolism and Disposition · 2004 · 642 citations

, , +17

Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical Pharmacology

Manuela Grimstein, Yuching Yang, Xinyuan Zhang et al. · Journal of Pharmaceutical Sciences · 2018 · 308 citations

, , +17

The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

Scott Grimm, Heidi J. Einolf, Steven D. Hall et al. · Drug Metabolism and Disposition · 2009 · 306 citations

, , +17

Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

Jae Wook Ko, Nadia Sukhova, David Thacker et al. · PubMed · 1997 · 210 citations

, , +17